 The FDA signed off Flexion Therapeutics Incs NASDAQ: FLXN Phase 1b proof of concept trial evaluating FX301 administered as a popliteal fossa block a commonly used nerve block in the foot and ankle-related surgeries in patients undergoing bunionectomy. FX301 combines NaV1.7 inhibitor funapide with thermosensitive hydrogel to facilitate administration as a peripheral analgesic nerve block. 